Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 12/20 | 0.46 |
| ▸ | FNTB | P49356 | 12/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 5/20 | 0.44 |
| ▸ | DRD3 | P35462 | 5/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7246204 | 1.00 | FNTA (0.46) | FNTAFNTBSIRT2SIRT1DRD2 | |
| SCHEMBL3300722 | 0.90 | SIRT2 (0.43) | FNTAFNTBSIRT2SIRT1HDAC1 | |
| SCHEMBL648876 | 0.82 | DPP4 (0.43) | SIRT1HDAC1HDAC8HDAC6 | |
| SCHEMBL653007 | 0.81 | BRD4 (0.47) | FNTAFNTBSIRT1 | |
| SCHEMBL10148387 | 0.81 | MTNR1A (0.42) | SIRT1 | |
| SCHEMBL430079 | 0.80 | MTNR1A (0.53) | SIRT1 | |
| SCHEMBL31043514 | 0.80 | MTNR1A (0.53) | SIRT1 | |
| SCHEMBL14113226 | 0.78 | MTNR1A (0.59) | FNTAFNTBSIRT2SIRT1HDAC1 | |
| SCHEMBL3284426 | 0.78 | MTNR1A (0.59) | FNTAFNTBSIRT2SIRT1HDAC1 | |
| SCHEMBL652622 | 0.78 | AADAT (0.44) | SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-20 | — | — | US | claimed |
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-7884113-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884113-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-7709647-B2 | Tetrahydroquinoline cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709647-B2 | Tetrahydroquinoline cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-14 | — | — | US | disclosed |
| EP-1644335-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20060160850-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-1644335-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005007628-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | FNTA 1368/4885FNTB 2071/4885SIRT2 1394/4885 |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | FNTA 1368/4885FNTB 2071/4885SIRT2 1394/4885 |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | FNTA 1874/4885FNTB 1450/4885SIRT2 879/4885 |
| US-20060160850-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | FNTA 1894/4885FNTB 1364/4885SIRT2 796/4885 |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | FNTA 1368/4885FNTB 2071/4885SIRT2 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.